权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Role of CREG1 in metabolic homeostasis

CREG1 在代谢稳态中的作用

基本信息

批准号：
10608346
负责人：
CHRISTOPH BUETTNER
金额：
$ 49.25万
依托单位：
RUTGERS BIOMEDICAL AND HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-02-16 至 2027-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10608346
关键词：
Ablation Adipose tissue Adult Beta Cell Binding Biochemical CRISPR/Cas technology Cell membrane Cell physiology Cell surface Cells Clinical Complementary DNA Complex Consumption CpG Islands DNA methyltransferase inhibition Databases Dependovirus Development Dilution Techniques Down-Regulation Electron Microscopy Endocytosis Endosomes Enzymes Epidemic Exhibits Exons Fasting Gene Delivery Genes Glucose Glucose Clamp Glucose Intolerance Glycoproteins Goals Hepatic Hepatocyte High Fat Diet Homeostasis Human Hyperinsulinism Immunofluorescence Immunologic Impairment In Vitro Insulin Insulin Receptor Insulin Resistance Insulin-Like Growth Factor I Insulin-Like Growth Factor II Intervention Knock-in Mouse Knock-out Knockout Mice Label Lead Link Liver Mediating Medical Membrane Metabolic Metabolic Diseases Methylation Missense Mutation Molecular Mus Mutagenesis Non-Insulin-Dependent Diabetes Mellitus Nutritional Obese Mice Obesity Oligosaccharides Overnutrition Pancreas Pathogenesis Pathway interactions Perfusion Physiologic pulse Physiological Proinsulin Protocols documentation Recycling Regulation Role Site Surface Surveys System Testing Tissues Tracer Vesicle Wild Type Mouse adenoviral mediated cell growth regulation cellular targeting diabetes pathogenesis gain of function genetic testing global health glucose production glycosylation human subject improved in vivo insulin granule insulin regulation insulin secretion insulin sensitivity insulin signaling islet knock-down live cell imaging loss of function mannose 6 phosphate mutant novel therapeutic intervention overexpression receptor receptor expression receptor recycling trafficking trans-Golgi Network

项目摘要

Project Summary Type 2 diabetes mellitus (T2DM) is caused by insulin resistance and reduced insulin secretion. Cellular repressor of E1A-stimulated genes 1 (CREG1), a small glycoprotein involved in membrane trafficking in the endocytic and secretory pathways, may be involved in the pathogenesis of T2DM, as suggested by the insulin resistance, glucose intolerance, elevated glycemia and hypoinsulinemia in whole-body Creg1 knockout mice. Gain- and loss-of-function studies using cultured hepatocytes and liver-specific Creg1 knockout mice demonstrate that CREG1 autonomously regulates cellular insulin signaling, insulin sensitivity, and the expression of insulin receptor on the plasma membrane. In pancreatic ?-cell-specific Creg1 knockout islets, increased proinsulin and diminished insulin levels lead to impaired insulin secretion. Furthermore, CREG1 expression is nutritionally regulated and is progressively downregulated by high-fat diet consumption. This project will test (1) whether loss of CREG1 inhibits insulin receptor recycling and consequently impairs insulin signaling and insulin action, (2) to what degree CREG1 downregulation contributes to insulin resistance in metabolic disease, and (3) whether Creg1 ablation impedes insulin granule trafficking and enhances insulin degradation. In the first Aim, we will delineate the role of CREG1 in the regulation of insulin receptor trafficking and its contribution to hepatic insulin action and cellular insulin signaling. We will restore CREG1 expression in high fat diet fed mice via adeno- associated virus-mediated CREG1 gene delivery and test if this improves insulin sensitivity and insulin signaling. In the second Aim, we will elucidate how loss of CREG1 leads to reduced ?-cell insulin content with a focus on proinsulin processing and insulin degradation. Pulse-chase labeling and live cell imaging, electron microscopy, and biochemical analysis combined with complex physiological study protocols will be used in the proposed studies. Our long-term goals are to elucidate how CREG1 regulates hepatic insulin action and ?-cell insulin secretion, and to target CREG1 to treat T2DM.

项目总结